Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,788.00-1.91%ETH$2,478.56-3.77%GOLD$4,172.90+0.38%OIL$91.02-0.51%
Smart Investors Daily
SID Premium
TK

NASDAQ · TKNO

Alpha Teknova, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$8.44

Down-$0.27 (-3.10%)

Updated Oct 9, 2026, 4:02 AM

SID Score

6.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
262.29M
P/E ratio
-14.39
Dividend yield
0.00%
52-week range
$1.91 – $9.48
Volume
252.95K
Avg. volume
238.53K

Price performance · TKNO

TKNO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

TKNO closed at $8.44 after 21 trading sessions, up 22.14% for the selected period.

Last close
$8.44
Period change
+22.14%
Period low
$6.71
Period high
$9.33
Daily close
View OHLC price history
TKNO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$8.64$8.64$8.38$8.44252.95K
Oct 7, 2026$8.62$8.88$8.34$8.71267.69K
Oct 6, 2026$9.06$9.4123$8.61$8.75376.96K
Oct 5, 2026$8.91$9.19$8.68$9.00480.13K
Oct 2, 2026$8.96$9.04$8.80$8.99249.32K
Oct 1, 2026$8.89$9.11$8.75$8.86344.32K
Sep 30, 2026$9.10$9.197$8.78$8.90288.03K
Sep 29, 2026$9.21$9.31$8.86$9.08349.68K
Sep 28, 2026$9.205$9.425$8.95$9.20222.48K
Sep 25, 2026$9.38$9.48$9.13$9.33291.89K
Sep 24, 2026$8.82$9.41$8.6891$9.29356.22K
Sep 23, 2026$8.69$9.35$8.5165$8.93381.7K
Sep 22, 2026$8.34$9.04$8.2801$8.77492.03K
Sep 21, 2026$7.87$8.38$7.66$8.34438.36K
Sep 18, 2026$7.39$7.915$7.24$7.79502.37K
Sep 17, 2026$7.40$7.56$7.00$7.45310.07K
Sep 16, 2026$6.96$7.17$6.82$7.11171.52K
Sep 15, 2026$6.79$6.93$6.65$6.90117.17K
Sep 14, 2026$6.72$6.86$6.33$6.82238.1K
Sep 11, 2026$7.01$7.07$6.67$6.71100.06K
Sep 10, 2026$6.86$6.93$6.71$6.9188.27K

Latest TKNO news

The latest Smart Investors Daily articles mentioning TKNO.

Stock researchCompany · Overview

TKNO research

Overview

Company profile and research snapshot.

Company profile

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.18
Implied upside
—
Analysts
12
TKNO recent ratings
DateFirmRatingTarget
Sep 17, 2026JefferiesBuy—
Aug 11, 2026BTIGBuy—
Aug 5, 2026Roth CapitalBuy—
Jul 10, 2024Stephens & Co.Overweight—
May 14, 2024Stephens & Co.Overweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissionsHOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc. (“Pluristyx”), today announced that Pluristyx is completing a Type II Drug Master File (DMF) for the PluriFreeze™ cryopreservation system for submission to the U.S. Food and Drug Administration (F

Yahoo · Sep 16, 2026

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround timeHOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today intr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By